- Home
- PENN vs HCM Comparison
PENN vs HCM Comparison
Compare PENN & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENN | HCM |
|---|---|---|
| Founded | 1972 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | PENN | HCM |
|---|---|---|
| Price | $21.88 | $10.17 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 13 | 1 |
| Target Price | ★ $20.83 | $13.75 |
| AVG Volume (30 Days) | ★ 3.5M | 57.9K |
| Earning Date | 04-23-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,362,900,000.00 | N/A |
| Revenue This Year | $6.85 | $20.60 |
| Revenue Next Year | $3.83 | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.65 | $9.77 |
| 52 Week High | $22.36 | $19.50 |
Technical Indicators
Market Signals| Indicator | PENN | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 65.49 | 30.89 |
| Support Level | $13.58 | N/A |
| Resistance Level | $22.36 | $15.75 |
| Average True Range (ATR) | 0.87 | 0.26 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 79.30 | 27.56 |
Price Performance
Historical ComparisonAbout PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 42 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 81% of total sales in 2025; 19% was from the interactive segment, which includes sports, i-gaming, and media revenue. The retail portfolio generates low-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/i-gaming technology and clientele, helping it form a leading digital position.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.